The OPUS-2 trial will also evaluate the safety, tolerability, and immune response of VAX-31 in adults aged 50 and older. But ...

Vaxcyte Inc (NASDAQ:PCVX) is among the best 52-week high US stocks to buy. Vaxcyte Inc (NASDAQ:PCVX) has completed enrollment ...

As wealthy nations scramble to secure stocks of oil, the result is higher prices for all and shortages in vulnerable ...

DaVita is set to announce its first-quarter results in May, with analysts forecasting a double-digit increase in the ...

However, Moderna's deep pipeline and innovative technology could eventually allow it to improve and deliver excellent returns ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Bhopal: City is facing an emerging public health concern as stocks of life-saving anti-rabies vaccines at JP Hospital are ...

PM UTC It will lose patent exclusivity within the next two years, but Merck has earned approval for a new, subcutaneous ...

In recent years, the healthcare sector as a whole has underperformed the broader market, yet there are still high-quality ...

U.S. stocks are flirting with a record Wednesday following their big rally the last two weeks on hopes that the global ...

Mutual fund AUM today is generally quite sticky. Investors are increasingly focused on long-term outcomes rather than ...

Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers.